AICAR vs Semaglutide
A side-by-side research comparison of AICAR and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AICAR | Semaglutide |
|---|---|---|
| Full name | AICAR (AMPK Activator / Exercise Mimetic) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | AICAR is converted intracellularly to ZMP, which mimics AMP and directly activates AMP-activated protein kinase (AMPK). AMPK activation shifts metabolism toward fat burning, mitochondrial biogenesis, and glucose uptake, mimicking effects of endurance exercise. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 258.23 Da | 4,114 Da |
| Half-life | Short | 7 days (168 hours) |
| Bioavailability | Injection (research); poor oral | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | Not established for humans | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Research only | Once weekly |
| Route | Injection (research) | Subcutaneous injection |
AICAR reported benefits
- AMPK activation (exercise-mimetic)
- Increased fat oxidation
- Mitochondrial biogenesis
- Improved endurance (animal models)
- Enhanced glucose uptake
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.